MAP2K7 and melanoma: Dimitriou et al. have reported a case of a female patient with stage IIID melanoma showed hair depigmentation after being treated by anti-PD1 antibody, BRAF and MEK inhibitors (Dimitriou et al., 2020), indicating a reduced peripheral tolerance to melanocytic self-antigen.